Biogen

Operating margin

—

Net margin

13.1%

Return on equity

7.1%

Return on assets

4.4%

Return on capital (ROCE)

—

Liabilities / assets

38.0%

Debt / equity

0.61×

Book value / share

$124.73

Revenue growth (YoY)

2.2%

Net income growth (YoY)

−20.8%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Accruals / assets

−3.1%clean

Beneish M-Score

-2.68normal

Piotroski F-Score

5/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• ZINBRYTAMay 27, 2016
• AVONEXMay 17, 1996

• Phase 1Active Not Recruitingreadout ~2025-09-30
  A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
• Phase 2Active Not Recruitingreadout ~2026-05-14
  A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
• Phase 3Active Not Recruitingreadout ~2026-07-31
  A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
• Phase 1Recruitingreadout ~2026-08-06
  A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old
• Phase 3Active Not Recruitingreadout ~2026-09-27
  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
• Phase 3Active Not Recruitingreadout ~2026-09-30
  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
• Phase 2/3Recruitingreadout ~2026-10-20
  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
• Phase 3Recruitingreadout ~2026-12-01
  A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

• Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Regulation FD disclosureMay 14, 2026
• Results of operationsApr 29, 2026
• Results of operationsApr 6, 2026
• Entered a material agreement · Other material eventMar 31, 2026
• Director / officer changeMar 11, 2026
• Director / officer change · Other material eventFeb 11, 2026
• Results of operationsFeb 6, 2026
• Results of operationsJan 14, 2026

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Corporate family

Spin-offs from Biogen (1)

• Bioverativ Inc.completedJan 31, 2017details

From the spin-off filings we track. Follow a company to walk its own history.